Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2023
A new study conducted by Baylor College of Medicine and presented at the American College of Cardiology Annual Scientific Session as well as the World Congress of Cardiology shows that an oral PCSK9 inhibitor called MK-0616...
Read Full NewsComplicated eligibility rules, stigma surrounding smoking and lung cancer, and confusion about the screening process continue to keep many high-risk patients from getting screened.
A recent post hoc analysis assesses whether PSA changes can predict survival outcomes in patients with metastatic or very high risk nonmetastatic prostate cancer.
The FDA says the increased risk of hematologic secondary primary malignancies with tazemetostat now outweighs the benefits of the drug; Ipsen pulls it from the market.
The BCL-2 inhibitor was granted accelerated approval based on findings from the phase 1/2 BGB-11417-201 study.
1.
In a study, immune detection of oral cancers is linked to obesity.
2.
Why breast cancer survivors don't take their medicine, and what can be done about it.
3.
Researchers have determined that malignancy hibernation will be the next front in the fight against breast cancer.
4.
finding fresh approaches to treating diffuse midline gliomas.
5.
Telehealth in the pandemic era resulted in fewer therapy interruptions.
1.
Understanding Iron Saturation Levels in Your Blood
2.
Thyroid Cancer and Insulin Resistance: Unraveling the Complex Interplay for Better Patient Outcomes
3.
The Next Generation of Precision: How Multi-Specific Antibodies are Redefining Oncology's Future - A 2025 Review
4.
The Ultimate Guide to Understanding Abiraterone and its Uses in Cancer Treatment
5.
The Truth About Marijuana and Its Effect on Mental Health
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part III
2.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part II
3.
Breaking Down PALOMA-2: How CDK4/6 Inhibitors Redefined Treatment for HR+/HER2- Metastatic Breast Cancer
4.
Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias
5.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge